Abstract
In a large cohort in rural South Africa, 73% of subtype-C-infected patients initiating highly active antiretroviral therapy achieved viral suppression. In patients with subsequent virological failure, an unexpected, rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated mutations was observed, whereas no thymidine analogue-associated mutations emerged. It appeared that several patients had drug-associated mutations prior to starting antiretrovirals, suggesting that transmission of resistance may have contributed to the accumulation of nonnucleoside reverse transcriptase inhibitor-mutations. Importantly, monitoring of HIV-RNA and prompt switch of treatment may prevent development of thymidine analogue-associated mutations.
Original language | English |
---|---|
Pages (from-to) | 2210-2 |
Number of pages | 3 |
Journal | AIDS |
Volume | 22 |
Issue number | 16 |
DOIs | |
Publication status | Published - 2008 |
Keywords
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- Drug Resistance, Viral
- HIV Infections
- HIV-1
- Humans
- Longitudinal Studies
- Mutation
- Reverse Transcriptase Inhibitors
- Rural Health
- South Africa